<?xml version="1.0" encoding="UTF-8"?>
<ref id="b9-1040138">
 <label>9.</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Rummel</surname>
    <given-names>MJ</given-names>
   </name>
   <name>
    <surname>Niederle</surname>
    <given-names>N</given-names>
   </name>
   <name>
    <surname>Maschmeyer</surname>
    <given-names>G</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multi-centre, randomised, phase 3 non-inferiority trial</article-title>. 
  <source>Lancet</source>. 
  <year>2013</year>;
  <volume>381</volume>(
  <issue>9873</issue>):
  <fpage>1203</fpage>â€“
  <lpage>1210</lpage>.
  <pub-id pub-id-type="pmid">23433739</pub-id>
 </mixed-citation>
</ref>
